In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

Key antigens of Leishmania species identified in the context of host responses in
Leishmania‐exposed individuals from disease‐endemic areas were prioritized for the development …

Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of improved
TB vaccines that boost or replace BCG is a major global health goal. ID93 + GLA-SE is a …

Background A vaccine that prevents pulmonary tuberculosis in adults is needed to halt
transmission in endemic regions. This trial aimed to assess the safety and immunogenicity of …

Abstract Design Safety and immunogenicity of a recombinant 14 kDa, fatty acid-binding
protein(FABP) from Schistosoma mansoni (rSm14) were evaluated through an open, non-…

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …

Most studies of T lymphocytes focus on recognition of classical major histocompatibility
complex (MHC) class I or II molecules presenting oligopeptides, yet there are numerous …